TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it has initiated a clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of its lead product candidate, tezampanel. The randomized, double-blind, placebo-controlled Phase I trial will enroll 18 healthy volunteers at a single center in the United States.

More: continued here

This entry was posted on Tuesday, June 10th, 2008 at 1:06 pm and is filed under Pain / Anesthetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.